Page 30 - Read Online

Page 12 of 14 Fujimoto et al. J Cancer Metastasis Treat 2021;7:66 https://dx.doi.org/10.20517/2394-4722.2021.157

22. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol
2006;24:181-9. DOI PubMed
23. Vargo JA, Patel A, Glaser SM, et al. The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-
cell lymphoma, nasal type, in the United States. Cancer 2017;123:3176-85. DOI PubMed
24. Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor
immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998;16:70-7. DOI PubMed
25. Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment.
J Clin Oncol 2000;18:54-63. DOI PubMed
26. Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol
Biol Phys 2004;59:1127-37. DOI PubMed
27. Yang CW, Wang CW, Hong RL, et al. Treatment outcomes of and prognostic factors for definitive radiotherapy with and without
chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma. J Radiat Res 2017;58:114-22. DOI PubMed PMC
28. Yang Y, Zhu Y, Cao JZ, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a
multicenter study. Blood 2015;126:1424-32; quiz 1517. DOI PubMed
29. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized
intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6. DOI PubMed
30. Egashira M, Kawamata N, Sugimoto K, et al. P-glycoprotein expression on normal and abnormally expanded natural killer cells and
inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999;93:599-606. PubMed
31. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer
1995;76:2351-6. DOI PubMed
32. Ribrag V, Ell Hajj M, Janot F, et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized
primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001;15:1123-6. DOI PubMed
33. Ribrag V, Ell Hajj M, Janot F, et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized
primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001;15:1123-6. DOI PubMed
34. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-
cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004;15:618-25. DOI PubMed
35. Wang B, Lu JJ, Ma X, et al. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma
of nasal cavity. Leuk Lymphoma 2007;48:396-402. DOI PubMed
36. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell
lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009;27:5594-600. DOI PubMed
37. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly
diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: consortium for Improving Survival of Lymphoma study. J Clin
Oncol 2009;27:6027-32. DOI PubMed
38. Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for
localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol 2014;93:1895-901. DOI PubMed
39. Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol
2005;130:860-8. DOI PubMed
40. Chen JS, Lin KH, Lin DT, Chen RL, Jou ST, Su IJ. Longitudinal observation and outcome of nonfamilial childhood haemophagocytic
syndrome receiving etoposide-containing regimens. Br J Haematol 1998;103:756-62. DOI PubMed
41. Uno M, Tsuchiyama J, Moriwaki A, et al. In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived
cell line, NK-YS, by etoposide and cyclosporine A. Br J Haematol 2001;113:1009-14. DOI PubMed
42. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or
refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol
2011;29:4410-6. DOI PubMed
43. Kwong YL, Kim SJ, Tse E, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage
I/II NK/T-cell lymphoma. Ann Oncol 2018;29:256-63. DOI PubMed
44. Liang R, Todd D, Chan TK, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995;13:666-
70. DOI PubMed
45. Nagafuji K, Fujisaki T, Arima F, Ohshima K. L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after
autologous peripheral blood stem cell transplantation. Int J Hematol 2001;74:447-50. DOI PubMed
46. Matsumoto Y, Nomura K, Kanda-Akano Y, et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell
lymphoma. Leuk Lymphoma 2003;44:879-82. DOI PubMed
47. Obama K, Tara M, Niina K. L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol
2003;78:248-50. DOI PubMed
48. Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell
lymphoma. Int J Hematol 2003;78:163-7. DOI PubMed
49. Jaccard A, Petit B, Girault S, et al. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and
leukemia and a review of the literature. Ann Oncol 2009;20:110-6. DOI PubMed
50. Qi S, Yahalom J, Hsu M, et al. Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian
population. Leuk Lymphoma 2016;57:2575-83. DOI PubMed PMC
51. Wang JH, Wang L, Liu CC, et al. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with